P
Perrin David
Publications - 7
Citations - 599
Perrin David is an academic researcher. The author has contributed to research in topics: Pitolisant & Modafinil. The author has an hindex of 4, co-authored 7 publications receiving 563 citations.
Papers
More filters
Journal ArticleDOI
An inverse agonist of the histamine h3-receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients
Jian-Sheng Lin,Yves Dauvilliers,Isabelle Arnulf,Hélène Bastuji,Christelle Anaclet,Régis Parmentier,Laurence Kocher,Masashi Yanagisawa,Philippe Lehert,Xavier Ligneau,Perrin David,Philippe Robert,Michel Roux,Jeanne Marie Lecomte,Jean Schwartz +14 more
TL;DR: H(3)-receptor inverse agonists could constitute a novel effective treatment of EDS, particularly when associated with modafinil, a currently-prescribed wake-promoting drug.
Journal ArticleDOI
BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology.
Xavier Ligneau,Perrin David,Laurent Landais,J.-C. Camelin,Thierry Calmels,Isabelle Berrebi-Bertrand,Jeanne-Marie Lecomte,Régis Parmentier,Christelle Anaclet,Jian-Sheng Lin,Valerie Bertaina-Anglade,C. Drieu la Rochelle,F. d'Aniello,A. Rouleau,Florence Gbahou,J.M. Arrang,Charon Robin Ganellin,Holger Stark,Walter Schunack,J C Schwartz +19 more
TL;DR: Preclinical data suggest that BF2.649 is a valuable drug candidate to be developed in wakefulness or memory deficits and other cognitive disorders.
Journal ArticleDOI
Brain histamine and schizophrenia: Potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649
Xavier Ligneau,Laurent Landais,Perrin David,Johanne Piriou,Marilyne Uguen,Emmanuel Denis,Philippe Robert,Régis Parmentier,Christelle Anaclet,Jian-Sheng Lin,Aude Burban,Jean-Michel Arrang,J C Schwartz +12 more
TL;DR: Observations suggest that H(3)-receptor inverse agonists/antagonists deserve attention as a novel class of antipsychotic drugs endowed with pro-cognitive properties.
Journal ArticleDOI
Preclinical evaluation of the abuse potential of Pitolisant, a histamine H3 receptor inverse agonist/antagonist compared with Modafinil
M Uguen,Perrin David,S Belliard,Xavier Ligneau,PM Beardsley,Jeanne-Marie Lecomte,J.-C. Schwartz +6 more
TL;DR: Pitolisant, a histamine H3 receptor inverse agonist/antagonist is under Phase III clinical trials for treatment of excessive daytime sleepiness namely in narcoleptic patients and its drug abuse potential was investigated using in vivo models in rodents and monkeys.
Journal ArticleDOI
Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
Stéphane Krief,Isabelle Berrebi-Bertrand,Isabelle Nagmar,Martin Giret,Simon Belliard,Perrin David,Marilyne Uguen,Philippe Robert,Jeanne-Marie Lecomte,Jean-Charles Schwartz,Olivier Finance,Xavier Ligneau +11 more
TL;DR: In this article, the authors compared different wake-promoting agents in terms of mechanism of action, efficacy, or safety, and concluded that pitolisant is a differentiated therapeutic option, when compared with psychostimulants, for the treatment of EDS, as this agent does not show any amphetamine-like properties within in vivo preclinical models.